Floatz logo

d-0316

EGFR Gene Mutation

Betta Pharmaceuticals Co., Ltd.Phase 2/3Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
81/ 100

Competitive context

31 Active assets in the EGFR Gene Mutation cohort.

Asset / SponsorPhaseRating
Osimertinib
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 3BB
Gefetinib
China Medical University Hospital
Phase 2/3BB
Carboplatin
Guangdong Provincial People's Hospital
Phase 3B
CIS-DIAMMINEDICHLOROPLATINUM II
Sichuan Cancer Hospital and Research Institute
Phase 3B
Cyclophosphamide
Hideho Okada, MD, PhD
Phase 2B

View all 50 →

Same molecule, other indications

d-0316 is also rated in:

non-small cell lung carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →